financetom
Business
financetom
/
Business
/
Global Payments Soars After Beating Q2 Earnings, Secures Major Sports Tech Deals
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Global Payments Soars After Beating Q2 Earnings, Secures Major Sports Tech Deals
Aug 7, 2024 9:23 AM

Global Payments Inc. ( GPN ) shares are trading higher on Wednesday after the company reported second-quarter results.

The company reported adjusted earnings per share of $2.93 (+12%), beating the street view of $2.90.

Quarterly sales of $2.57 billion beat the analyst consensus of $2.32 billion (+6%). 

Adjusted operating margin increased by 40 basis points to 45.2%.

Global Payments’ Board of Directors has approved a dividend of $0.25 per share, payable on Sept. 27, 2024, to shareholders of record as of Sept. 13, 2024.

Also Read: US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A ‘Growth Scare’ And Not ‘Calamity’

“We continue to see good momentum with our point-of-sale solutions, and are pleased to announce a new agreement with Diamond Baseball Holdings to serve as the official commerce technology partner for its Minor League Baseball franchises in the United States and Canada,” said Cameron Bready, chief executive officer.

“We also signed new stadium partnerships with multiple UK football clubs in the second quarter, including Newcastle, Birmingham City, and Nottingham Forest,” Bready added.

Outlook: Global Payments ( GPN ) projects FY24 revenue between $9.17 billion and $9.3 billion (reiterated), slightly below the $9.22 billion estimate.

The company sees adjusted EPS between $11.54 and $11.70, compared to the $11.60 estimate.

Price Action: GPN shares are trading higher by 7.6% to $100.10 at last check Wednesday.

Read Next:

Move Over Yen, Yuan Carry Trades Could Be Next Ticking Bomb, Warns Strategists: ‘But It’s Below The Danger Levels We Monitor’

Image created using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Nov 13, 2025
Overview * Biofrontera Q3 revenue of $7 mln missed analyst expectations due to advanced purchases in 2024 * Adjusted EBITDA for Q3 was negative $6 mln, missing analyst estimates * Company completed purchase of US Ameluz and RhodoLED assets, reducing royalty payments Outlook * Company anticipates substantial 4Q25 and annual revenue growth due to price normalization * Biofrontera expects enhanced...
Copyright 2023-2026 - www.financetom.com All Rights Reserved